Interim pooled findings from the ACTIV-4a, ATTACC, and REMAP-CAP trials suggest that full-dose prophylactic anticoagulation is considerably beneficial for moderately ill COVID-19 patients irrespective of the initial D-dimer level.

For the primary endpoint, organ support-free days to day 21, in hospitalized patients initially not in the intensive care unit (ICU), the therapeutic dose approach had a proportional odds ratio meeting the criteria for superiority over typical prophylactic dose - 1.57 with low D-dimer, 1.53 with high D-dimer, and 1.51 with missing D-dimer. Overall, the rates were around 16% vs. 23% in post hoc analysis, reported Ryan Zarychanski, leading both ATTACC and REMAP-CAP trials… (Medpage Today)